Thursday 31 May 2018

Institutional Pharmacies Market Size to Grow Exponentially During 2016 - 2024

Institutional Pharmacies Market: Overview
Pharmacies, or pharmaceutical shop is a kind of shop which is engaged in the selling and distribution of pharmaceutical and healthcare related products (drugs, devices and others) and services (dosing training, medical advice, information about side effects and precautions) to the patients and customers. Pharmacy shop is an inseparable aspect of pharmaceutical sciences field and is one of the most growing field in the healthcare industry.
Pharmacies are broadly classified on the basis of sales nature and end customers, namely, retail pharmacy and institutional (consultant) pharmacy. Retail pharmacies comprises traditional, independent pharmaceutical shops, which are engaged in satisfying the customer needs and interaction with routine customers, whereas, institutional pharmacies offer more emphasis on provision of long-term care facilities, products and services, and on maintenance of patient data and medication history and records.
Although, the institutional pharmacies were not directly involved in patient interaction, due to rising geriatric population and changes in the pharmacy practices, institutional pharmacies have started consulting and guiding the patients directly. Sometimes, institutional pharmacies are considered similar to hospital pharmacies, but former is different on the basis of principles of operating the business and end users.
Institutional Pharmacies Market: Drivers and Trends
The market of institutional pharmacies is expected to grow steadily in upcoming period, owing to various market drivers, such as, benefits of bulk purchase, increased need of institutional pharmacies, rise in geriatric population where patient data monitoring has became essential. In addition, rising prevalence of chronic disease propelling the needs of long-term care, large employment opportunities and rising awareness amongst the pharmaceutical graduates and hospitals regarding the benefits of institutional pharmacies against the traditional pharmacies. Rising geriatric population and chronic disease prevalence are some of the most important drivers of this market.
According to Center for Disease Control and Prevention (CDC), by the 2050, the aged population in the U.S. would exceed 89 million, twice of the 2013. Institutional pharmacies play an important role in maintaining the clinical database and guiding the geriatric patients regarding medications and its associated issues.
Further, increased prevalence of chronic disease is another growth propeller of the institutional pharmacies. According to International Diabetes Federation, 382 million people across the globe are suffering from diabetes, by 2013, and this number is expected to grow to 592 million by the end of 2035.
Institutional Pharmacies Market: Restraints
The institutional pharmacies play a vital role in the maintenance of patient medication database related to such chronic diseases and helps in the estimation of further treatments. On the other hand, lack of awareness, high initial costs and stringent government regulations are the major hurdles, expected to impose a threat to the market growth. In addition to this, shrinking medical reimbursement and increasing consolidation of the industry are additional threats to the market growth. The major opportunities include government programmes and campaigns for the promotion of this concept in the world, regulation of laws and rules related to institutional pharmacies would enhance the institutional pharmacies across the globe.
Institutional Pharmacies Market: Key Players
Major players operating in this market include OmniCare, PharMerica, BGS Pharmacy Partners, Golden Horizons, NuScriptRx, Uvanta, Chem Rx Corporation and others. Due to extensive trend of consolidation of the industry, many major players are employing the strategies of acquisitions and partnerships to expand their product portfolio and geographic presence. For instance, Chem Rx Corporation formed partnership with PharMerica to expand the business in New Jersey and New York, U.S. Similarly, BGS Pharmacy Partners acquired Spectrum Pharmacy Services, LLC, to expand the business in Las Vegas, U.S.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Rare Hematology Market to reflect a CAGR of 6.2% Over the Forecast Period 2017 - 2022

Transparency Market Research (TMR) in a new market study reports that the global vitreous tamponades market is highly fragmented with the presence of small and medium sized players. A distinct feature of the market is that each region is dominated by a select number of players. For instance, the vitreous tamponades market in North America is dominated by Novartis AG and Valeant Pharmaceuticals that hold more than 50% of market share. Likewise, the European market for vitreous tamponades is characterized by the dominance of Dutch Ophthalmic Research Center B.V., AL. CHI. MI.A. srl, and Fluron GmbH.
A notable trend observed in the market is the thrust on research and development by keen companies to introduce newer products. This is to serve the demand for case - specific products for specialty medical procedures.
As per estimates of the TR report, the global vitreous tamponades market stood at a valuation of US$69.3 mn in 2016and is likely to present an opportunity worth US$89.9 mn by the end of 2025 at a CAGR of 3.0% for the forecast period between 2017 and 2025.
In terms of product, liquid tamponades emerged as the lucrative segment holding 53.9% of the market in 2016. The supremacy of the segment is due to the widespread use of liquid tamponades over gaseous tamponades. The ophthalmology clinics send-use segment led the global vitreous tamponades market vis-à-vis revenue in 2016. Geography-wise, North America holds the leading share amongst other regions in vitreous tamponades market.
Rising Incidence of Diabetes Leading to Retinal Conditions Boosts Growth
“Steady growth of vitreous tamponades market is witnessed due to increasing incidence of retinal detachments, diabetic retinopathy, macular pucker, and other retinal disorders,” explains the lead author of the study. As per statistics of the American Academy of Ophthalmology, 17 million cases of proliferative diabetic retinopathy were recorded globally in 2013. Diabetic retinopathy exclusively requires vitrectomy, which in turn, is stoking demand for vitreous tamponades. This is because modern vitrectomy techniques rely heavily on vitreous substitutes for the reattachment of the retina. Moreover, as per statistics of the International Diabetes Federation, around 300 million diabetes cases were reported in 2010 globally and this figure is likely to reach 438 million by 2030. The rising incidence of diabetes that has a high risk to cause diabetes retinopathy and other retinal disorders is stoking the demand for tamponades to prevent impaired vision and even blindness.
Prevalence of Retinal Detachment Stokes Demand for Tamponades for Vitrectomy
Further, the rising incidence of retinal detachment and other vitreoretinal disorders that can be corrected with vitrectomy is positively influencing the vitreous tamponades market. Vitrectomy involves surgical removal of the vitreous humor to be replaced with synthetic substitutes known as vitreous tamponades. In the human eye, vitreous humor is a vital component that acts as nutrition and as a refractive medium. In the event of trauma or upon aging, the vitreous humor disintegrates leading to tearing or detachment of the highly fragile retina.
Apart from this, growing elderly population globally is also considered as one of the key factors boosting the growth of vitreous tamponades market. This is because the aged population has a high risk of retinal breaks that requires effective treatment.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Vitreous Tamponades Market to Attract a Revenue of US$ 89.9 Million by the End of 2025

Transparency Market Research (TMR) in a new market study reports that the global vitreous tamponades market is highly fragmented with the presence of small and medium sized players. A distinct feature of the market is that each region is dominated by a select number of players. For instance, the vitreous tamponades market in North America is dominated by Novartis AG and Valeant Pharmaceuticals that hold more than 50% of market share. Likewise, the European market for vitreous tamponades is characterized by the dominance of Dutch Ophthalmic Research Center B.V., AL. CHI. MI.A. srl, and Fluron GmbH.
A notable trend observed in the market is the thrust on research and development by keen companies to introduce newer products. This is to serve the demand for case - specific products for specialty medical procedures.
As per estimates of the TR report, the global vitreous tamponades market stood at a valuation of US$69.3 mn in 2016and is likely to present an opportunity worth US$89.9 mn by the end of 2025 at a CAGR of 3.0% for the forecast period between 2017 and 2025.
In terms of product, liquid tamponades emerged as the lucrative segment holding 53.9% of the market in 2016. The supremacy of the segment is due to the widespread use of liquid tamponades over gaseous tamponades. The ophthalmology clinics send-use segment led the global vitreous tamponades market vis-à-vis revenue in 2016. Geography-wise, North America holds the leading share amongst other regions in vitreous tamponades market.
Rising Incidence of Diabetes Leading to Retinal Conditions Boosts Growth
“Steady growth of vitreous tamponades market is witnessed due to increasing incidence of retinal detachments, diabetic retinopathy, macular pucker, and other retinal disorders,” explains the lead author of the study. As per statistics of the American Academy of Ophthalmology, 17 million cases of proliferative diabetic retinopathy were recorded globally in 2013. Diabetic retinopathy exclusively requires vitrectomy, which in turn, is stoking demand for vitreous tamponades. This is because modern vitrectomy techniques rely heavily on vitreous substitutes for the reattachment of the retina. Moreover, as per statistics of the International Diabetes Federation, around 300 million diabetes cases were reported in 2010 globally and this figure is likely to reach 438 million by 2030. The rising incidence of diabetes that has a high risk to cause diabetes retinopathy and other retinal disorders is stoking the demand for tamponades to prevent impaired vision and even blindness.
Prevalence of Retinal Detachment Stokes Demand for Tamponades for Vitrectomy
Further, the rising incidence of retinal detachment and other vitreoretinal disorders that can be corrected with vitrectomy is positively influencing the vitreous tamponades market. Vitrectomy involves surgical removal of the vitreous humor to be replaced with synthetic substitutes known as vitreous tamponades. In the human eye, vitreous humor is a vital component that acts as nutrition and as a refractive medium. In the event of trauma or upon aging, the vitreous humor disintegrates leading to tearing or detachment of the highly fragile retina.
Apart from this, growing elderly population globally is also considered as one of the key factors boosting the growth of vitreous tamponades market. This is because the aged population has a high risk of retinal breaks that requires effective treatment.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Rheumatology Therapeutics Market to Become Worth US$ 52.96 Billion by 2025

Prominent companies operating in the global rheumatology therapeutics market are AbbVie, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. etc. Some other key players in the market are Amgen, Inc., Janssen Biotech, Inc., Novartis AG, Genentech, Inc., Sanofi, and Takeda Pharmaceutical.
A report by Transparency Market Research uncovers after in-depth study that the global rheumatology therapeutics market will rise at a lackluster CAGR of 2.7% from 2017 to 2025 to become worth US$ 52.96 bn by 2025 from US$41.88 bn in 2016.
The various drug classes in the global rheumatology therapeutics market are disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAID’s), corticosteroids, uric acid drugs, etc. The DMARDs, which is a group of medicines or combination of medicines used to treat rheumatic diseases by blocking the inflammation, accounts for maximum share in the market at present. They are categorized into two major types - biologic DMARDs and synthetic DMARDs. By rising at a 2.6% CAGR from 2017 to 2025 the segment is expected to retain its dominant share in the upcoming years.
Geographically, the key segments of the global rheumatology therapeutics market are North America, South America, Europe, Asia Pacific, and the Middle East and Africa. Of them, North America leads the market with dominant share on account of a burgeoning geriatric population highly susceptible to various kinds of rheumatology disorders. Further, uptake of biologics and biosimilar products for treating moderate to severe rheumatoid arthritis and superior healthcare facilities has also proved beneficial to the market in the region.
Burgeoning Elderly Population Drives Growth
Rheumatology is the multidisciplinary approach towards the diagnosis and treatment of the various rheumatic disease which includes clinical problems in joints, soft tissues, heritable connective tissue disorders, vasculitis, and autoimmune diseases. Rheumatic disease is associated with inflammation that affects the bones, tendons, ligaments, and sometimes organs.
At the forefront of driving growth in the global rheumatology therapeutics market is the ever-increasing elderly population worldwide and swift approval of new drugs for treating various rheumatic diseases. In August 2017, for example, the FDA approved DUZALLO drug by Ironwood Pharmaceuticals, Inc. and AstraZeneca. It is the first and only therapy that leverages two types of mechanisms in gout with only one pill. Again, in 2017, Kevzara (Sanofi and Regeneron Pharmaceuticals, Inc.) got the FDA approval to treat adult patients with moderately to severely active rheumatoid arthritis (RA). In 2017, AbbVie Inc., a global leader in anti-rheumatic drugs, announced its four potential candidates, which are Upadacitinib, Risankizumab, ABBV-599, and ABT-981, that are in different phases of clinical trials to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis (OA).
Investment into Research and Development Benefits Market
Other factors positively influencing the market are rising knowledge among people about rheumatic diseases and emergence of cost-effective rheumatology therapeutics. Further, increasing investment in research and development is likely to bolster the growth of global rheumatology therapeutics market during the forecast period.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Wednesday 30 May 2018

Burkitt Lymphoma Therapeutics Market Scope and Opportunities Analysis 2017 - 2025

Burkitt lymphoma (BL) may be defined as an aggressive rare disorder that constitutes approximately 1% to 2% of all non-Hodgkin lymphomas. Burkitt lymphoma is known as one of the most aggressive forms of lymphoma, with a doubling time of approximately 24 hours. The term was coined after an Irish surgeon named Denis Burkitt, who first described the lymphoma in 1958, and was the first to successfully compile description of significant number of cases with the disorder. A range of intensive therapy regimen is available to choose from which depends upon local practice. The CODOX-M/IVAC is the most commonly administered regimen, first introduced as pediatric regimen in 1980 by Magrath et.al. Various regimen for Burkitt lymphoma (BL) are R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R regimen, and other high-intensive regimens. Burkitt lymphoma is represented by three clinical sub-types: endemic Burkitt lymphoma (eBL), immunodeficiency-associated Burkitt lymphoma (iBL), and sporadic (sBL).
These clinical sub-types share similar morphological and immunophenotypic features, while conform largely with respect to genetic makeup, and differ in exhibiting few clinical features as well as incidence pattern. Sporadic Burkitt lymphoma (sBL) is a rare disorder generally affecting all age groups. It accounts for approximately 1% of adult lymphomas and reported in areas lacking endemic malaria. Endemic Burkitt lymphoma (eBL) is predominantly a pediatric disease or disorder, accounting for about 30% to 50% of pediatric cancer in regions with holoendemic malaria. Endemic Burkitt lymphoma (eBL) clinically differs by affecting facial bones especially the jaw. Immunodeficiency-associated Burkitt lymphoma (iBL) accounts for 10% to 40% of all HIV (Human Immunodeficiency Virus) associated lymphomas and was the first to be recognized in HIV setting.
The CODOX-M/IVAC regimen includes cytarabine, cyclophosphamide, doxorubicin, etoposide, high-dose cytarabine, IT methotrexate, leucovorin, vincristine/ifosfamide. BFM/GMALL/NHL regimen generally consists of pre-phase treatment with prednisone and cyclophosphamide, which is then commenced by alternating chemotherapy with six cycles including doxorubicin, dexamethasone, ifosfamide, high-dose methotrexate, teniposide, cytarabine, and vincristine. It also includes triple IT therapy with cytarabine, dexamethasone, and methotrexate. Hyper-CVAD regimen which was initially developed for acute lymphoblastic leukemia includes four cycles of hyperfractionated cyclophosphamide, dexamethasone, vincristine, and doxorubicin.
CALGB and LMB regimens utilize prednisone and cyclophosphamide as a pre-phase cycle, followed by alternating chemotherapy cycles depending upon the risk. DA-EPOCH-R regimen consists of different approach with low concentration chemotherapy agents being exposed for long period of time as compared to that of other high-intensive regimen, comprising infusional EPOCH (cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone). This regimen is specifically used in order to provide continuous exposure of cytotoxic agents to tumor cells and to bring about decrease in toxicity. Many variations of short-cycle, high intensive regimens are being developed and used in addition to these regimens.
The global Burkitt lymphoma (BL) therapeutics market can be segmented based on clinical type, drug therapy regimen, distribution channel, and region. In terms of clinical type, the market can be classified into endemic BL (eBL), immunodeficiency-associated BL (idBL), and sporadic variant (sBL). Based on drug therapy regimen, the global Burkitt lymphoma (BL) therapeutics market can be categorized into R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R, and other high-intensive regimens. In terms of distribution channel, the market can be divided into drug stores, hospital pharmacy, online pharmacy, retail pharmacy, and others.
In terms of region, the global Burkitt lymphoma (BL) therapeutics market can be segmented into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America.
Key players in the global Burkitt lymphoma (BL) therapeutics market are Bedford Laboratories, Sun Pharma, Seattle Genetics, Inc., Sanofi, Mayo Clinic, Pfizer, Inc., Merck KGaA, and Cellerant Therapeutics, Inc., among others.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Ringworm Treatment Market Latest Trends and Future Growth Study by 2025

Ringworm is a common fungal infection of skin. Tinea is the medical term used for ringworm. The infection is caused by skin fungi called dermatophytes. Ringworm infection can cause scaly, red, and round patches on skin. It can also cause patches of hair loss, itching, blisters, and scaling of scalp. The infection can affect various areas such as skin of scalp, feet, beard, and groin. Ringworm is highly contagious and can be transmitted through animals. The infection can be treated successfully with certain antifungal and over-the-counter medicines.
The global ringworm treatment market is expected to grow at a rapid pace. High incidence and prevalence of skin disease are the major factors driving the global ringworm treatment market. Increase in prevalence of bacterial and viral infections boosting R&D activities, rise in awareness about antifungal treatment, and novel treatment for diseases also propel the global market. Furthermore, affection toward pets leading to transmission of disease, increase in combination therapies, rise in health care funding, and promising pipeline are anticipated to drive the global ringworm treatment market during the forecast period. However, lack of awareness in some developing countries about antifungal treatment and complication during the regulatory approvals are the factors likely to restrain the global ringworm treatment market during the forecast period.
The global ringworm treatment market can be segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market can be categorized into steroids, antifungals, anti-infectives, and others. The antifungals segment is expected to dominate the market during the forecast period due to specificity and effectiveness of the drugs on the infection. Based on route of administration, the global ringworm treatment market can be bifurcated into oral and topical. The topical segment is expected to hold a major share of the global market during the forecast period due to increase in sale of over-the-counter topical medicines for treatment. In terms of distribution channel, the global market can be divided into hospital pharmacies, drug stores, retailers, and e-commerce.
Geographically, the global ringworm treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is projected to dominate the global ringworm treatment market in terms of revenue, followed by Europe. Factors such as rise in incidence of skin diseases, increase in adoption of pets in the region, growth of the health care sector, and increase in awareness drive the ringworm treatment market in the region. Furthermore, the prominent players are focusing on Europe to strengthen their positions. The market in Asia Pacific is anticipated to expand at the fastest growth rate during the forecast period due to rise in health care expenditure, increase in geriatric population, surge in disposable income, prevalence of chronic diseases, focus of global pharmaceutical companies on Asia Pacific, increase in adoption of exotic pets leading to transmission of the disease, and unhealthy lifestyle in the rural areas.
Key players operating in the global ringworm treatment market have adopted various strategies such as launch of products that are cost effective and efficient, mergers and acquisitions, geographical expansion, and strategic alliance. Prominent players in market are Perrigo Company plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., and Glenmark Pharmaceuticals Inc.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Gastroparesis Treatment Market Share and Growth Factors Impact Analysis 2017 - 2025

Gastroparesis, also known as delayed gastric emptying, can be defined as a disease of the stomach muscles or the nerves controlling these muscles that causes the stomach muscles to stop functioning. It affects the spontaneous movement of the stomach muscles. Impaired mobility of the stomach muscles leads to emptying of the stomach. Gastroparesis occurs due to damage to the vagus nerve either because of injury or illness. Gastroparesis that commonly occurs among people is known as idiopathic gastroparesis, indicating that the actual cause of the disease is unclear. Diabetes is other common cause of gastroparesis, as high blood sugar levels leads to slow damage of the vagus nerve causing gastroparesis. The common symptoms of the disease include nausea, feeling of fullness, gastroesophagial reflux, abdominal bloating, lack of appetite, and pain in the stomach area.
The global gastroparesis treatment market is anticipated to record moderate growth during the forecast period. Growth of the market can be attributed to increase in prevalence of diabetes mellitus among people, rise in number of surgeries being performed which could lead to post-operative gastroparesis, introduction of novel drugs, and focus of market players on research and development to launch specific drugs for the treatment of gastroparesis. Additionally, untapped opportunities in the emerging markets such as India and China are likely to fuel the growth of the market. However, usage of non-prescription drugs, side effects of available gastroparesis drugs, and stringent regulatory environment for the approval of new drugs are expected to restrain the market during the forecast period. Moreover, lack of awareness among people about gastroparesis and available treatments is anticipated to hamper market growth.
The global gastroparesis treatment market can be segmented based on drug class, type, distribution channel, and region. In terms of drug class, the market can be categorized into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment dominated the market in 2016, owing to effectiveness, ease of availability, high usage, and applicability of these medications in treating gastroparesis. Based on type, the global gastroparesis treatment market can be classified into diabetic gastroparesis, chronic gastroparesis, idiopathic gastroparesis, and post-operative gastroparesis. The post-operative gastroparesis segment is anticipated to expand at a rapid pace during the forecast period, owing to increase in the number of surgeries such as transplantation. In terms of distribution channel, the market can be divided into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment dominated the market in 2016 and the trend is anticipated to continue during the forecast period.
Geographically, the global gastroparesis treatment market can be segmented into five major regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America was the largest market in terms of revenue in 2016 and the trend is anticipated to continue during the forecast period. Growth of the market in the region can be attributed to rise in the number of diabetic patients. Diabetic gastroparesis is considered one of the major forms of gastroparesis affecting the population. Europe is expected to be the next attractive market for gastroparesis treatment. However, sluggish economy in the region is likely to hamper the growth of the market. The market in Asia Pacific is anticipated to expand at a high CAGR owing to factors such as government focus on enhancing health care facilities, rise in patient population, and increase in product approvals.
Leading players operating in the global gastroparesis treatment market are Boston Scientific Corporation, Cardinal Health, Inc., C. R. Bard, Inc., Abbott Laboratories, Medtronic, Salix Pharmaceuticals, Inc., Janssen Global Services, LLC, Teva Pharmaceuticals, Kimberly-Clark Corporation, Rhythm Pharmaceuticals, Inc., Alfa Wassermann SPA, and Evoke Pharma, among others.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Disposable Surgical Kits Market Competitive Landscape Analysis with Forecast by 2025

Disposable surgical kits include surgical to be used in surgery, drapes for delivery kits, and disposable blood donor kits. Disposable surgical kits are cost-effective, help in eliminate instrument cleaning and recycling, and reduce infection associated with surgery. Thus, increasing the efficiency of hospitals and surgical centers by increasing their productivity. Disposable surgical kits were confined only to IV bags, blood bags, swabs, and others in the recent past. Increasing demand for cost-effectiveness and efficiency has led to an increased focus on the usage of single-use and disposable products. Increasing technological development has also paved the way for high quality and highly efficient disposable surgical kits, as compared to traditional or reusable surgical kits.
The disposable surgical kit market is expected to expand during the forecast period. The usage of disposable kits has increased rapidly in various healthcare settings, as an increasing number of healthcare professionals are employing disposable surgical kits, as compared to re-usable kits, due to the advantages associated with disposable kits. Disposable surgical kits are highly practical in their usage, as they reduce the cost of storing in an aseptic condition. These kits also reduce the cost of sterilization associated with re-usable kits, and they are easy to dispose.
The global disposable surgical kits market can be segmented based on material type, procedure type, end user, and region. Based on material type, the market can be segregated into non-woven fabrics and film. In terms of procedure type, the global disposable surgical kits can be classified into orthopedic, neurosurgery, general surgery, women’s health, urology, ophthalmic, ENT, and others. Based on end-user, the market can be into hospitals, clinics, specialty clinics, ambulatory surgical centers, research & academic institutes, trauma centers, and others. Rising trend toward ophthalmic surgery in the last few years is estimated to considerably boost the demand for disposable surgical kits, particularly in cataract and retinal surgeries.
Major drivers of the global disposable surgical kits market include developed healthcare infrastructure, increasing awareness about hygiene in developing economies, favorable government regulation in promoting the usage of disposable surgical kits, and increasing mergers and acquisitions in the healthcare medical devices sector. Major restraints of the global disposable surgical kits market include generation of significant amounts of waste, thus increasing environmental apprehensions, and existence of certain impurities in these disposable surgical kits, which are likely to contaminate the content.
In terms of geography, the global disposable surgical kits market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a prominent share of the global disposable surgical kit market due to high demand, presence of major manufacturers, and increasing product launches in the region. Europe is expected to follow North America in terms of market share. Asia Pacific is estimated to provide lucrative opportunity to the disposable market during the forecast period. High demand for surgical kits increasing awareness regarding hospital acquired infection during and after surgical procedure, along with increasing competition between global and regional manufacturers is anticipated to drive the market in the region. The market in Latin America and Middle East & Africa is projected to expand during the forecast period under the influence of major economies.
The disposable surgical kits market in Latin America and Middle East & Africa is anticipated to expand at a significant growth rate during the forecast period due to developed healthcare infrastructure, increasing economic stability in countries such as Brazil.
Major players operating in the global disposable surgical kits market include Johnson & Johnson, 3M, Medtronic, Dynarex, Smith & Nephew, LSL Healthcare, Inc.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Remicade Biosimilar Market Current Trends and Future Aspect Analysis 2017 - 2025

Demand for biological products is high for the treatment of a large number of diseases. However, demand for biosimilar products is increasing to lower health care costs. Biosimilar products are derived in reference to biological products and have similar safety, efficacy, purity, and effectiveness when compared to the original products. Biosimilar can be characterized as a sort of biologic item that is profoundly like an as of now FDA approved biologic drug, known as reference drug. Biosimilars are drugs approved by the U.S. FDA and the European Medicine Agency (EMA) and show no clinical and meaningful difference from the reference biological product. These biosimilar products can be approved only for indications which are previously approved for the reference biological product by authorized regulatory bodies.
In 1998, the U.S. FDA licensed Remicade (infliximab), a monoclonal antibody originally produced by Janssen Biotech, Inc. and Merck & Co. in partnership. Its primary indication included Crohn’s disease in both adult and pediatric patients. It is also indicated for the treatment of ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, and rheumatic arthritis when given in combination with methotrexate. The U.S. FDA approved biosimilar to Remicade named Inflectra on April 05, 2016. Pfizer launched Inflectra in the market at 15% discount on the original market price of the reference product. However, in April 2017, another biosimilar Renflexis (infliximab-abda), a tumor necrosis factor to Remicade by Samsung Bioepis and Merck & Co., was approved to be launched into the market. It is approved for almost all the indications that were approved under Remicade such as ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, rheumatic arthritis, and ankylosing spondylitis.
Increase in incidence of autoimmune disorders such as rheumatoid arthritis, and psoriasis, patent expiry of branded drugs, and rise in health care costs drive the Remicade biosimilar market. Additionally, faster entry of Biosimilars into the Europe market leads to cost reduction and faster medicines accessibility help to grow this market. However, serious side effects associated with the drug could lead to fatality. This factor restraints the market.
The global Remicade biosimilar market can be segmented based on approved indication and region. In terms of approved indication, the market can be categorized into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis. Ulcerative colitis and rheumatoid arthritis show higher demand due to increase in number of cases of these diseases. Psoriasis also increase market demand owing to increase in the cases of autoimmune diseases. Based on region, the global Remicade biosimilar market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market owing to high incidence of autoimmune diseases and increase in geriatric population. Europe is the second largest market for Remicade. Easy access to biosimilar medications in the region drives the market. India, southeast Asia, and China are emerging markets for biosimilar medicines because of changing lifestyle and increase in healthcare facilities in these regions.
Key players in the global Remicade biosimilar market comprise Alvogen, Napp Pharmaceuticals, Janssen Biotech, Inc., Merck &Co., Pfizer, Inc., Cell Trion, and Nippon Kayaku.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Tuesday 29 May 2018

Active Implantable Medical Devices Market to Present an Opportunity Worth US$ 20.73 Billion by 2025

A number of leading players in the global active implantable medical devices are investing extensively in the research and development of their new implants, finds a new research report by Transparency Market Research (TMR). These players are also involving into partnerships with hospitals and dermatologists to increase the sales of their products.
Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Sonova Holding AG, LivaNova Plc, BIOTRONIK SE & Co. KG, Cochlear Ltd., William Demant Holding A/S, Nurotron Biotechnology Co. Ltd., and MED-EL Medical Electronics are some of the leading players in the global market for active implantable medical devices. These players are expected to use innovative strategies to widen their product portfolio in order to improve their market position over the next few years, states the research report.
According to the research report, the opportunity in the global active implantable medical devices market is likely to expand at a CAGR of 4.40% over the period from 2017 to 2025 and reach a value of US$20.73 bn by the end of the forecast period. Implantable cardioverter defibrillators (ICDs) are registering a relatively greater demand and are anticipated to continue doing so over the forthcoming years.
Hospitals, ambulatory surgery centers (ASCs), and specialty clinics have surfaced as the key end users of active implantable medical devices across the world. Hospitals, among these, are expected to report a higher uptake of these device in the years to come. In terms of the region, North America led the global market in 2016 with a share of 33.5%. Researchers project the scenario to remain more or less the same over the forthcoming years, notes the market study.
Increasing prevalence of Cardiovascular and Neurological Disorders to Boost Demand
“The increasing prevalence of cardiovascular and neurological disorders among people across the world is the main factor that has been influencing the growth of the global market for active implantable medical devices,” says the author of this research study. Apart from this, the market’s growth is also influenced by frequent product approvals and continual product launches. Companies are introducing innovative and novel products so as to maintain competitive advantage, carve new markets and lay foundation for sustained business growth, states the research report.
Challenges Regarding Usage of Active Implantable Medical Devices to Hamper Growth
On the flip side, challenges related to the usage of active implantable medical devices, such as device failure and concerns related to cybersecurity, may hamper the growth of the worldwide market for active implantable medical devices in the years to come. However, the rising healthcare expenditure associated with the increasing number of patients with cardiovascular diseases (CVDs) and neurological disorders is likely to fuel the demand for active implantable medical devices, supporting the growth of this market over the next few years, reports the market study.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Monocyte Activation Tests Market to Register CAGR of over 14.0% from 2017 to 2025

Limited supply of MAT test kits & reagents to Restrain Global Market Expansion
According to WHO (World Health Organization), only 12.5 million blood donations are collected globally, and approximately half of these are collected in high-income countries, which is home to 19% of the world’s population. Limited number of healthy blood donors hinders the production of MAT kits & reagents which ultimately effects the growth of the market. Moreover, introduction of pyrogen test in different applications. Pyrogen test was introduced for pharmaceutical products such as drugs and immunological products. Presently, it is being used on medical devices, implants, purification of water, and food & beverages industries.
Reagents Dominates the Monocyte Activation Tests Market
The report offers detailed segmentation of global monocyte activation tests market based on product type, source, application and end user. Among the product segment, reagents segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Factors attributed to the higher share of the reagent segment in the global market include frequent replacements leading to increasing usage of reagents when compared to test kits. Monocyte activation tests kits segment is likely to register comparatively higher growth rate in terms of value in the global monocyte activation tests (MAT) market during the forecast period owing to continuous innovations in the product technologies by major market players.
Cell line based source likely to gain market share
In terms of source, the monocyte activation tests market has been segmented into blood based, peripheral blood mononuclear cell (PBMC) based and cell line based. Blood based segment accounted for the largest market share in 2016. Blood-based MAT exhibits a natural human reaction to pyrogens and provides a better estimate of pyrogenic activity of preparations than the limulus amebocyte lysate (LAL) or rabbit pyrogen test (RPT). The MAT kit with a cell line is able to detect all human pyrogens and has an advantage of stability of the assay based on a cell line. Also, it does not depend on the blood donor.
Medical Devices & Lipid Parenteral: Top Two Application Areas of Monocyte Activation Tests
By application, the monocyte activation tests market has been further classified into lipid parenteral, dialysis liquids, toxic/immune-modulatory drugs, blood products and medical devices. Medical devices segment accounted the largest market share in 2016 due to the increasing number of medical devices in market demands for the pyrogen test before approval in the market. Additionally, lipid parenteral products include vitamins, steroids, and hormones, many of which are applied intramuscularly using a lipidic carrier. These products are required to be tested for pyrogen before launch in the market. This is a key factor driving the segment. Toxic/immune-modulatory drugs is likely to expand at CAGR more than 15.0% from 2017 to 2025.
Pharmaceuticals Industry is Promising End User for the Monocyte Activation Tests Market
In terms of end-user, the monocyte activation tests market is segmented into pharmaceuticals industry, biotechnology industry, medical devices industry and others. Pharmaceutical industry segment accounted for the major share in 2016 accounting for a share of more than 30.0% in terms of revenue, while biotechnology industry is anticipated to grow at higher CAGR during the forecast period due to the increasing demand of pyrogen testing by biotechnology companies to determine the presence of bacterial toxins in the process. Moreover, pyrogen testing has been introduced into medical devices, implants, purification of water, and food & beverage industries. These increased application areas are increasing demand for MAT products.
Asia Pacific Region is Expected to Grow with the Highest Rate During the Forecast Period.
North America region is expected to witness the highest share in 2016 and is anticipated to grow by a significant growth rate during the forecast period. Key players domiciled in the region, increase in research and development activities, and new drug approvals are the major factors attributed to the dominance of the region. In North America market U.S. is projected to dominate the market. Europe region is anticipated to grow by an impressive rate during the forecast period. Owing to the growth of animal-free endotoxin detection trend in the region, MAT is expected to gain significant market share in Europe during the forecast period. In Europe market Germany is dominant and Spain is likely to expand at highest CAGR due various research being conducted in the country. Asia Pacific region is expected to grow with the highest rate during the forecast period. Increase in focus of key players to expand presence in the region, large untapped population, and rise in healthcare awareness fuel the growth of the monocyte activation tests market in Asia Pacific. Countries such as India, China, and Japan in Asia Pacific are poised to be the most promising markets for monocyte activation tests in the near future, expand at high CAGRs during forecast period.
Key Players such as Merck & Co., Inc., Charles River Laboratories International, Inc., Becton, Dickinson and Company are Likely to Continue to Lead the Global Monocyte Activation Tests Market
The report also provide profiles of leading players operating in global monocyte activation tests market include Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories International, Inc., Sanquin, Microcoat Biotechnologie GmbH, Becton, Dickinson and Company, SOLVIAS AG, and Lonza Group. Innovation is a key strategic for the leading players, for instance, in March 2016, the Scientist magazine listed Merck’s CRISPR epigenetic activator among its ‘Top 10 Innovations of 2015’. This innovation was devised from the understanding that the life sciences research segment lacked an effective method for the activation of endogenous gene expression. Additionally expansion through merger and acquisition is followed by many players operating in this market. For example, in July 2015, Charles River Laboratories International, Inc. acquired Celsis International, Ltd., a leading provider of rapid testing systems for bacterial contamination. This addition to its product portfolio has expanded the company’s existing portfolio of microbial solutions.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Urinary Incontinence Treatment Devices Market Value to Reach US$ 3.65 Billion by 2025

Transparency Market Research (TMR) has published a new report titled “Urinary Incontinence Treatment Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. According to the report, the global urinary incontinence treatment devices market was valued at US$ 1.97 Bn in 2016 and is projected to expand at a CAGR of over 7.0% from 2017 to 2025. High prevalence of urinary incontinence and overactive bladder across the globe and technological advancements such as non-implantable electrical stimulation devices are likely to boost the growth of the global urinary incontinence treatment devices market from 2017 to 2025. North America and Europe are projected to dominate the global urinary incontinence treatment devices market in the next few years due to rise in demand for minimally invasive surgery/devices for urinary incontinence treatment, favorable medical reimbursement policies, and rapidly increasing geriatric population. Asia Pacific is projected to account for significant market share by 2025. This is attributed to large urinary incontinence patient base in highly populated countries such as India and China, large geriatric population in Japan and increase in adoption of technologically advanced products in Japan, Australia & New Zealand, and South Korea. Surge in adoption of technologically advanced products manufactured by key manufacturers such as Medtronic plc, Boston Scientific Corporation, and Cogentix Medical is likely to drive the global urinary incontinence treatment devices. The urinary incontinence treatment devices market in Europe is expected to expand at the highest CAGR of 7.0% from 2017 to 2025.
High Prevalence of Urinary Incontinence and Overactive Bladder to Fuel Global Market Expansion
Urinary incontinence is one of the highly prevalent and largely underreported and under-diagnosed urological disorder worldwide, affecting millions of people having severe impact on physical, psychological as well as emotional health. Women are more affected than men and the incidence increases with age. Several factors such as weak pelvic floor muscles, urethral sphincters, obesity, pregnancy & childbirth, urinary tract infection, neurological disorders, and other related factors cause urinary incontinence. An estimated 200 million people across the globe are affected by some form of urinary incontinence or bladder problem. Stress urinary incontinence is the most common form affecting millions of people globally. Various studies suggest that 24% to 45% of women above 30 years suffer from stress urinary incontinence. Large number of patients with stress urinary incontinence and overactive bladder symptoms is projected to fuel the growth of the global urinary incontinence treatment devices market during the forecast period.
Electrical Stimulation Devices to be Most Attractive Product Segment
The report offers detailed segmentation of the global urinary incontinence treatment devices market based on product, incontinence type, and end-user. In terms of product, the electrical stimulation devices segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Factors attributed to the high share of the segment include rise in demand for minimally invasive/wearable and non-implantable electrical stimulation devices to strengthen the pelvic floor muscles, high success rates with electrical stimulation devices, and favorable medical reimbursement policies in developed countries for implantable electrical stimulation devices. Development and launch of new electrical stimulation devices for percutaneous tibial nerve stimulation for the treatment of overactive bladder (such as Medtronic plc’s NURO System) is projected to drive the segment during the forecast period. Moreover, recent launch of wearable electrical stimulation device INNOVO by Atlantic Therapeutics and rise in demand for FDA-approved over-the-counter electrical stimulation device by InControl Medical is estimated to propel the segment during the forecast period.
Urge Urinary Incontinence Segment Dominates the Market, Followed by Stress Urinary Incontinence
In terms of incontinence type, the urge incontinence segment is projected to dominate the global urinary incontinence treatment market during the forecast period. The segment is estimated to expand at a CAGR of 7.2% from 2017 to 2025. Millions of people across the globe are affected by overactive bladder leading to urge incontinence. Dominance of the urge incontinence segment is attributed to comparatively high cost of treatment devices for urge incontinence, especially implantable electrical stimulation devices, than other treatment devices/methods. Therefore, rise in incidence of urge incontinence, increase in adoption of electrical stimulation devices for overactive bladder treatment, and estimated new product launch in this segment is projected to contribute to the growth of the segment during the forecast period.
Hospitals Segment Dominates the Market, Followed by Ambulatory Surgery Centers
In terms of end-user, the hospitals segment is projected to account for dominant share of the global urinary incontinence treatment devices market during the forecast period. The segment is likely to expand at a CAGR of 7.0% from 2017 to 2025. The ambulatory surgery centers segment is projected to account for the second leading share of the global urinary incontinence treatment devices market during the forecast period. High share of the segment is attributed to increase in number of surgical procedures for the treatment of all the types of urinary incontinence and favorable medical reimbursement policies for medical devices in most of the developed and developing countries. The home use segment is projected to expand at an exponential growth rate during the forecast period. Availability and high adoption of over-the-counter electrical stimulation and non-invasive treatment devices for effective management of urinary incontinence are the key factors driving the home use segment.
Huge Incremental Opportunity in Europe Region
In terms of revenue, North America is likely to continue to dominate the global urinary incontinence treatment devices market during the forecast period owing to early adoption of technologies, high patient pool of urinary incontinence, and easy availability and lucrative medical reimbursement policies in the U.S. and Canada. Europe is projected to be the second largest and most attractive market for urinary incontinence, with highest attractiveness index. The market in the region is expected to expand at a high CAGR of 7.0% during the forecast period due to high prevalence and rise in incidence of urinary incontinence in the region, increase in adoption of technologically advanced products, large base of medical devices companies, and large number of products in the pipeline phase for the treatment of urinary incontinence. The market in the U.K. is projected to expand at the highest CAGR during the forecast period. The country is likely to gain market share by the end of 2025. An estimated 15,000 mid-urethral sling surgical procedures (MUS) in women are performed in the U.K. Moreover, high incidence of post radical prostatectomy urinary incontinence in men is likely to accelerate the growth of the market in the country during the forecast period. Asia Pacific is estimated to be the second fastest growing market for urinary incontinence treatment devices owing to vast population in countries such as India and China, large geriatric population in Japan, and overall improving health care facilities in this region.
A Key Trend of New Product Development and Launch in the International Market is Observed among the Leading Players.
The report also provides profiles of leading players operating in the global urinary incontinence treatment devices market. Boston Scientific Corporation, C. R. Bard, Inc. (Becton, Dickinson and Company.), Coloplast Group, Promedon Group, Medtronic plc, and Ethicon US, LLC. (Johnson & Johnson) are the major players offering products with proprietary technologies. Several key companies have introduced mini slings for minimally invasive placement of mid-urethral slings with polypropylene sling material. In March 2016, Medtronic plc launched the NURO System, percutaneous tibial neuromodulation device for the treatment of overactive bladder. The NURO System is the second product in the market after Urgent PC by Cogentix Medical that targets the tibial nerve stimulation for the pelvic floor strengthening. Other prominent players in the global urinary incontinence treatment devices market include ZSI Surgical Implants, S.R.L., Incontrol Medical LLC, Hollister Incorporated, Atlantic Therapeutics Group Ltd., B. Braun Melsungen AG, A.M.I. GmbH, and Teleflex Incorporated.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)